touchPANEL DISCUSSION Expanding options for HER2 advanced breast cancer: Taking trial data to the clinic
Three experts discuss emerging treatments for HER2-directed therapies for advanced breast cancer and the implications for clinical practice
Dr Laura Biganzoli
Oncology Department, Hospital of Prato, Prato, Italy
CHAIR
Panelists:
Introduction
Dr Laura Biganzoli welcomes the expert panel and introduces the discussions covering expanding treatment options for HER2 breast cancer
view bio and disclosures 1/4 Next ChapterProgress with HER2-targeted therapies in advanced breast cancer
The panel discusses recent key data for trastuzumab deruxtecan, tucatinib and margetuximab from clinical trials in HER2+ breast cancer
view bio and disclosures 2/4 Next ChapterMaintaining HER2-targeted therapies: How to manage adverse events
The expert panel considers key adverse events for emerging agents in HER2-positive breast cancer and strategies for managing them
view bio and disclosures 3/4 Next ChapterNovel HER2-directed approaches: Implications for future practice
The expert panel discusses novel approaches for addressing key challenges in the management of HER2-positive breast cancer
view bio and disclosures 4/4 Take CE/CME TestOverview & Learning Objectives
Overview
In this activity, experts in breast cancer discuss the efficacy of emerging HER2-targeted therapies for advanced breast cancer and consider mitigation strategies for key adverse events. They conclude with a review of other novel HER2-directed treatments.
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of oncologists, breast cancer specialists, nurse specialists involved in the management of advanced breast cancer.
Disclosures
All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Faculty
Dr Laura Biganzoli discloses: Advisory board/panel discussion fees from AstraZeneca, Daiichi Sankyo, Eisai, Novartis, Pfizer, Pierre Fabre; consultancy fees from AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Novartis, Pfizer and Pierre Fabre; grant/research support from Celgene, Genomic Health and Novartis.
Dr Peter Fasching discloses: Advisory board/panel discussion fees from Agendia, AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Gilead, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sandoz, Sanofi Aventis and SeaGen; grant/research support from Biotech and Cephid.
Dr Sonia Pernas discloses: Advisory board/panel discussion fees from AstraZeneca, Daiichi Sankyo, Eisai, Pierre Fabre, Polyphor, Roche and SeaGen.
Content Reviewer
Kaitlin Hendrix, ARNP – Advisory Board – Sanofi-Genzyme, Daiichi-Sankyo, and Novartis (All relationships terminated)
Touch Medical Director
Alison Scott has no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have any questions regarding credit please contact cpdsupport@usf.edu
Accreditations
Physician
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Nurses
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 0.75 contact hours may be earned by learners who successfully complete this continuing professional development activity. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE activity.
This activity is awarded 0.75 ANCC pharmacotherapeutic contact hour.
ILNA
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
Disclaimer: ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditator/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
Date of original release: 11 November 2021. Date credits expire: 11 November 2022.
If you have any questions regarding credit please contact cpdsupport@usf.edu
Learning Objectives
After watching this activity, participants should be better able to:
- Evaluate the latest efficacy data for different HER2-targeted therapies in advanced breast cancer
- Apply appropriate monitoring for and management of adverse events in patients receiving HER2-targeted therapies
- Describe how novel approaches to HER2-targeting for advanced breast cancer in development may impact clinical practice
Faculty & Disclosures
Dr Laura Biganzoli
Oncology Department, Hospital of Prato, Prato, Italy
Laura Biganzoli is the Acting Director for the Medical Oncology Unit and Director of the Breast Center in the Oncology Department of the Hospital of Prato in Italy.
Dr Biganzoli’s research focuses on breast cancer and geriatric oncology, and she has extensively lectured and published in these fields. read more
Dr Biganzoli is a representative of the European Society for Medical Oncology/International Society of Geriatric Oncology (ESMO/SIOG) Cancer in Elderly Working Group, chair of the Science and Education committee of SIOG, and Board member of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). She is also a member of a committee engaged in writing national guidelines for the Associazione Italiana di Oncologia Medica (AIOM) and a member of the Advanced Breast Cancer (ABC) Consensus Panel.
Dr Laura Biganzoli discloses: Advisory board/panel discussion fees from AstraZeneca, Daiichi Sankyo, Eisai, Novartis, Pfizer, Pierre Fabre; consultancy fees from AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Novartis, Pfizer and Pierre Fabre; grant/research support from Celgene, Genomic Health and Novartis.
Dr Peter Fasching
University Hospital Erlangen and Comprehensive Cancer Center, Erlangen-EMN, Erlangen, Germany
Dr Peter Fasching is Associate Professor of Gynecology and Obstetrics at the Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. read more
Dr Fasching holds a professorship in translational medicine. He is interested in the discovery and translation of novel therapeutic targets in cancer treatment, with a current focus on cancers in women. He specializes in the individualization of cancer therapies, including the personalization of breast cancer prevention, and the integration of molecular and imaging characteristics into screening for breast cancer. He is also interested in the discovery of novel molecular targets for breast cancer prevention drugs that possess more favourable benefit–risk profiles. More recently, a substantial part of his work has included big data and machine learning to support novel drug target discovery.
Dr Fasching has co-authored more than 630 peer-reviewed research articles, and his research is funded by the National Institutes for Health (NIH) (USA), the European Union, the German Ministry for Health, the German Ministry for Economy and the German Ministry for Education and Research. He is a member of several societies including the American Society of Clinical Oncology, the German Society for Breast Diseases and the European Society for Medical Oncology.
Dr Peter Fasching discloses: Advisory board/panel discussion fees from Agendia, AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Gilead, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sandoz, Sanofi Aventis and SeaGen; grant/research support from Biotech and Cephid.
Dr Sonia Pernas
Catalan Institute of Oncology, and Faculty of Medicine, University of Barcelona, Barcelona, Spain
Dr Sonia Pernas is an oncologist with extensive clinical expertise in breast cancer and interest in clinical and translational research. read more
Dr Pernas’ primary research interest is in HER2-positive breast cancer and gene expression. Other areas of interest include biomarkers of response/resistance to therapy, identification of novel actionable target genes and their use to support rational sequencing strategies.
Dr Pernas has extensive clinical research experience, having been involved, both as principal investigator (PI) and co-PI, in many phase 1 to 4 clinical and window-of-opportunity trials in breast cancer. She has also collaborated in multiple translational research projects with national and international institutions.
Dr Pernas serves as a Board Member of the Spanish academic research group in oncology, SOLTI.
Dr Sonia Pernas discloses: Advisory board/panel discussion fees from AstraZeneca, Daiichi Sankyo, Eisai, Pierre Fabre, Polyphor, Roche and SeaGen.
Register to touchONCOLOGY for FREE
- Peer-reviewed journals and expert opinions
- Interactive CME and e-learning modules
- Video conference highlights
